Specify Company / Ticker to Get the Summary
Dividend History OTLK
Dividend Analytics OTLK
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–OUTLOOK THERAPEUTICS INC
OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey. Address: 111 S. Wood Avenue, Iselin, NJ, United States, 08830
Analytics
WallStreet Target Price
8.60 USDP/E Ratio
0.53Dividend Yield
–Financials OTLK
Results | 2019 | Dynamics |